Photo by finnnyc from unsplash
ABSTRACT There are few data on Bacillus Calmette-Guérin (BCG) therapy for upper urinary tract carcinoma in situ (UUT CIS). We retrospectively evaluated the efficacy and tolerability of BCG therapy for… Click to show full abstract
ABSTRACT There are few data on Bacillus Calmette-Guérin (BCG) therapy for upper urinary tract carcinoma in situ (UUT CIS). We retrospectively evaluated the efficacy and tolerability of BCG therapy for 41 patients [52 renal units(RUs)] with UUT CIS. Of 52 RUs, complete response was achieved in 47 (90%). The 5-year recurrence-, progression-free survival rates were 60.2% and 74.2%, respectively. Adverse events were observed in 31 (76%) patients, but most of them were mild. The scheduled instillations were completed in 31 (74%) of 42 patients. Our results demonstrated that BCG therapy for UUT CIS was satisfactory with high efficacy and tolerability.
Journal Title: Cancer Investigation
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!